enicepatide vs THDBH120

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

enicepatide

Developed by Roche and partners

Phase 3 in Obesitypeptide
Reliable signal

NCT06525935 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled Phase 2 trial in 469 adults with obesity and at least one weight-related condition. Enicepatide 24 mg produced significantly greater weight loss than placebo at week 48, 22.5% placebo-adjusted by one analysis method and 18.3% by another, both p<0.001, meeting the trial primary comparison.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2027 · NCT07589686 (registry estimate)

Reported efficacy

Percent Change in Body Weight from Baseline to Week 48: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) (met)

Result source: NCT06525935

THDBH120

Developed by Tonghua Dongbao Pharmaceutical

Phase 2 in Obesitypeptide
Weak signal

NCT06951945 · Phase 1 · completed

The trial was randomized, double-blind, and placebo-controlled, which is a sound design. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s) (78 days): Phase Ib multiple-dose, randomized, double-blind, placebo-controlled study: THDBH120 led to weight loss of up to 9.36% at six weeks. The two lower-dosed regimens led to weight loss of 7.38% after four weeks and 8.03% after six. Three dosing regimens that involved increasing doses every two or four weeks all showed significance against placebo. (not_applicable)

Result source: NCT06951945

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointenicepatideTHDBH120
Body weight, % change—Trial running · NCT07670416—Not reported
Weight loss of 5% or more—Trial running · NCT07670416—Not reported
Weight loss of 10% or more—Trial running · NCT07670416—Not reported
Waist circumference, change (cm)—Trial running · NCT07670416—Not reported

Body weight, % change

enicepatide
—Trial running · NCT07670416
THDBH120
—Not reported

Weight loss of 5% or more

enicepatide
—Trial running · NCT07670416
THDBH120
—Not reported

Weight loss of 10% or more

enicepatide
—Trial running · NCT07670416
THDBH120
—Not reported

Waist circumference, change (cm)

enicepatide
—Trial running · NCT07670416
THDBH120
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

THDBH120: no structured comparison results are available for Obesity.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

enicepatide
Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) NCT06525935 · Phase 2 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: enicepatide's landscape · THDBH120's landscape